#contributionControlled evidence validates a distinct target
The trial demonstrates large placebo-controlled reductions in attacks with FXIIa inhibition, extending the clinical evidence beyond existing C1-INH and kallikrein-directed approaches.
↳ Research in context; Results, primary efficacy analysis
#methodological rigourConcealed allocation and complete efficacy accounting
Interactive-response allocation, masked participants and investigators, volume-normalised syringes, and complete ITT attack-rate data protect the primary comparison from avoidable execution bias.
↳ Methods, Randomisation and masking; Statistical analysis
#methodological rigourSystematic assessment of short-term treatment harms
Adverse events were defined, MedDRA-coded, and assessed alongside special-interest events, laboratory findings, and anti-drug antibodies. Table 2 reports events and patient denominators by treatment group.
↳ Methods, Procedures and Outcomes; Table 2